Foghorn Therapeutics (FHTX) vs NRX Pharmaceuticals (NRXP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
NRX Pharmaceuticals (NRXP) has outperformed Foghorn Therapeutics (FHTX) over the past year, losing 21.0% versus a loss of 52.7%. Over five years, FHTX leads with a -83.1% price change compared with -97.2% for NRXP. NRX Pharmaceuticals is the larger company by market cap ($125.6 million vs $124.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FHTX | NRXP |
|---|---|---|
| Share price | $2.09 | $2.90 |
| Market cap | $124.12M | $125.56M |
| 1-day change | +6.09% | -1.36% |
| YTD return | -61.30% | +7.01% |
| 1-year return | -52.71% | -20.98% |
| 5-year return | -83.12% | -97.17% |
| EPS (TTM) | $-0.98 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.61 | $5.06 |
| 52-week low | $1.79 | $1.62 |
| Distance from 52-week high | -72.54% | -42.63% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +187.08% | +1227.59% |
| Average volume | 611.95K | 874.85K |
| Shares outstanding | 59.39M | 43.30M |
| Employees | 106 | 29 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRXP has outperformed FHTX by 31.7 percentage points over the past year.
About Foghorn Therapeutics
FHTX stock →Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Healthcare · Biotechnology · 106 employees
About NRX Pharmaceuticals
NRXP stock →NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments.
Healthcare · Biotechnology · 29 employees
FHTX vs NRXP FAQ
Which is bigger, Foghorn Therapeutics or NRX Pharmaceuticals?
NRX Pharmaceuticals (NRXP) is larger, with a market capitalization of $125.56M compared with $124.12M for Foghorn Therapeutics (FHTX).
Which stock has performed better over the past year, FHTX or NRXP?
NRXP returned -20.98% over the past 12 months, compared with -52.71% for FHTX (price return, excluding dividends). Past performance does not predict future results.
Are Foghorn Therapeutics and NRX Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.